Abdulrahman Elrabaa

· Assigned portfolios:

• SPIMACO Neuroscience portfolio (Entapro, Zolinda, Quetta Xr, Levetam Xr, Zonam, Zolonia). Launching all these products across the GCC with 100% Growth YOY.
• Anti-infectives portfolio (Klavox Tablet & Suspension), Achieving 114% Growth YOY in Klavox range across 2021/2022 with highest sales ever-achieved in GCC History.
• Additional Role: Training Our Sudan team and Launching Neuroscience portfolio (Zolinda, Zementa, Quetta Xr, Olenza ODT & Levetam Xr)

· In-charge of Day-to-day product management in terms of product cycle development, implementing marketing objectives, strategies & ensuring their execution across GCC with a total TGT of 15 Million USD.

· Introduction and launch of new products: this will include pre-launch activities, market research & analysis, branding with different platforms & promotional materials with sales team training & preparation.

· Participate in planning sales promotion and advertising in support of existing products, and support the marketing director in determining market strategies and sales tactics to achieve product objectives.

· Monitoring competitors’ promotion, pricing, product positioning and marketing tactics by product/business segment as well as their product line performance and initiate dynamic strategies that positively drives business.

· Managing and establishing the KOLs and stakeholders network in necessary specialties.

• 2016-2018: Launching Lorine FM & Velox - Achieving 130% Rofenac-D & 186% Peptazol (1st Year)
• 2018:In-charge of Iron Range (Ferose & Ferosac) + Ceclor Range with 40% Growth YOY.
• 2019-2021: Proton,Hepavir, Lorine FM & Velox (Best achiever GCC with highest target contribution)

• Working on Bausch & Lomb Opthalmology line: Artelac, Dexagel & Corneregel.
• Launching Thrombexx (recombinant hirudin IV) for ICU.
• Betolvex and acute care products (ciprodiazole, extrauma)
• Achieving quarterly targets and KPl's.